Wellesley, MA – According to filings with the U.S. Securities and Exchange Commission, Auron Therapeutics is raising $48,249,997.00 in new funding. Sources indicate as part of senior management President, Katharine Yen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Auron Therapeutics
Auron Therapeutics aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and reprogram cancer tissue to a more normal phenotype.

To learn more about Auron Therapeutics, visit http://aurontx.com/

Contact:
Katharine Yen, President
310-922-5881
https://www.linkedin.com/in/kate-yen-448b22108/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved